Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Silada Kanokrungsee, Tanaporn Anuntrangsee, Jutamas Tankunakorn, Ploychompoo Srisuwanwattana, Poonkiat Suchonwanit & Kumutnart Chanprapaph. (2021) Rituximab Therapy for Treatment of Pemphigus in Southeast Asians. Drug Design, Development and Therapy 15, pages 1677-1690.
Read now
Read now
Issam Hamadah, Muzamil A. Chisti, Mansoor Haider, Yousef Binamer, Saad Alajlan, Yousif Aleyouni & Abdullah Alfadley. (2019) Rituximab/IVIG in pemphigus – a 10-year study with a long follow-up. Journal of Dermatological Treatment 30:2, pages 170-175.
Read now
Read now
Shawn Shetty & A. Razzaque Ahmed. (2017) Rituximab in the treatment of pemphigus. Expert Opinion on Orphan Drugs 5:1, pages 99-109.
Read now
Read now
Anne Rübsam, Richard Stefaniak, Margitta Worm & Uwe Pleyer. (2015) Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opinion on Biological Therapy 15:7, pages 927-933.
Read now
Read now
Articles from other publishers (31)
Elham Daneshvar, Soheil Tavakolpour, Hamidreza Mahmoudi, Maryam Daneshpazhooh, Amir Teimourpour, Saeed Aslani & Kamran Balighi. (2022)
Elevated serum level of B‐cell activating factor (
BAFF
) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B‐cell depletion therapies combined with
anti‐BAFF
agents
. International Journal of Dermatology 62:4, pages 567-574.
Crossref
Crossref
Denise Miyamoto, Juliana Olivieri Gordilho, Claudia Giuli Santi & Adriana Maria Porro. (2022) Epidermolysis bullosa acquisita. Anais Brasileiros de Dermatologia 97:4, pages 409-423.
Crossref
Crossref
Huijie Yuan, Meng Pan, Hongxiang Chen & Xuming Mao. (2022) Immunotherapy for Pemphigus: Present and Future. Frontiers in Medicine 9.
Crossref
Crossref
Vinay Kulkarni, Swaraj Potdar & Pallavi Shirol. (2021) Rituximab in childhood pemphius vulgaris: A case report. Indian Journal of Drugs in Dermatology 7:2, pages 88.
Crossref
Crossref
Emily F. Cole, Naveed Sami & Ron J. Feldman. (2020) Updates on diagnosis and management of autoimmune blistering diseases. Giornale Italiano di Dermatologia e Venereologia 155:1.
Crossref
Crossref
Vinod K. Sharma, Vishal Gupta, Neetu Bhari & Vishwajeet Singh. (2019) Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long‐term follow‐up. International Journal of Dermatology 59:1, pages 76-81.
Crossref
Crossref
Michal Kuten-Shorrer, Reshma S. Menon & Mark A. Lerman. (2020) Mucocutaneous Diseases. Dental Clinics of North America 64:1, pages 139-162.
Crossref
Crossref
Urmi Khanna, Ariana M. Ellis & Anthony P. Fernandez. (2019) Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases. Current Treatment Options in Rheumatology 5:4, pages 290-312.
Crossref
Crossref
Carolyn J. Kushner, Shiyu Wang, Napatra Tovanabutra, Donald E. Tsai, Victoria P. Werth & Aimee S. Payne. (2019) Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. JAMA Dermatology 155:12, pages 1404.
Crossref
Crossref
N. van Beek, D. Zillikens & E. Schmidt. (2019) Aktuelle Therapie des PemphigusTherapy of pemphigus. Der Hautarzt.
Crossref
Crossref
Fereshteh Salarvand, Zahra Fatehi, Maryam Shahali, Kamran Balighi, Maryam Ghiasi, Robabeh Abedini, Hamidreza Mahmoudi, Soheil Tavakolpour, Cheyda Chams‐Davatchi & Maryam Daneshpazhooh. (2019) “Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran”: A multiple cross‐sectional study. Dermatologic Therapy 32:2, pages e12827.
Crossref
Crossref
Esther Q. Wang & Dedee F. Murrell. 2019. Cutaneous Biometrics. Cutaneous Biometrics
1
24
.
Amy Huang, Raman K. Madan, Lauren Bonomo & Jacob Levitt. 2018. Biologic and Systemic Agents in Dermatology. Biologic and Systemic Agents in Dermatology
343
349
.
Lauren N. Albers, Yuan Liu, Na Bo, Robert A. Swerlick & Ron J. Feldman. (2017) Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. Journal of the American Academy of Dermatology 77:6, pages 1074-1082.
Crossref
Crossref
Alice Cho, Bridget Bradley, Robert Kauffman, Lalita Priyamvada, Yevgeniy Kovalenkov, Ron Feldman & Jens Wrammert. (2017) Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI Insight 2:12.
Crossref
Crossref
Tae Hyung Kim, Yuri Choi, Sang Eun Lee, Jung Min Lim & Soo-Chan Kim. (2017) Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up. The Journal of Dermatology 44:6, pages 615-620.
Crossref
Crossref
Michael Kasperkiewicz, Christoph T. Ellebrecht, Hayato Takahashi, Jun Yamagami, Detlef Zillikens, Aimee S. Payne & Masayuki Amagai. (2017) Pemphigus. Nature Reviews Disease Primers 3:1.
Crossref
Crossref
Christoph T. Ellebrecht & Aimee S. Payne. (2017) Setting the target for pemphigus vulgaris therapy. JCI Insight 2:5.
Crossref
Crossref
Kyle Amber & Michael Hertl. 2017. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
767
774
.
Eran Cohen-Barak, Doron Sonnenscien, Michael Ziv, Ayelet Shani-Adir & Dganit Rozenman. (2016) Kaposi's sarcoma in a patient with pemphigus vulgaris. International Journal of Dermatology 55:1, pages 85-88.
Crossref
Crossref
Virendra N. Sehgal, Deepika Pandhi & Ananta Khurana. (2015) Biologics in dermatology: adverse effects. International Journal of Dermatology 54:12, pages 1442-1460.
Crossref
Crossref
R.J. Feldman. (2015) Paradoxical worsening of pemphigus vulgaris following rituximab therapy. British Journal of Dermatology 173:3, pages 858-859.
Crossref
Crossref
A. Razzaque Ahmed & Shawn Shetty. (2015) A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmunity Reviews 14:4, pages 323-331.
Crossref
Crossref
S. Ojaimi, K. O'Connor, M. W. Lin, M. Schifter & D. A. Fulcher. (2015) Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris. Internal Medicine Journal 45:3, pages 284-292.
Crossref
Crossref
Kyle T. Amber, Rüdiger Eming & Michael Hertl. 2015. Personalized Treatment Options in Dermatology. Personalized Treatment Options in Dermatology
135
146
.
Fabiana Marnetto, Letizia Granieri, Paola Valentino, Marco Capobianco, Marisa Pautasso & Antonio Bertolotto. (2014) CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study. Journal of Neuroimmunology 277:1-2, pages 127-133.
Crossref
Crossref
Frank A. Santoro, Eric T. Stoopler & Victoria P. Werth. (2013) Pemphigus. Dental Clinics of North America 57:4, pages 597-610.
Crossref
Crossref
Athanasios Mavropoulos, Timoklia Orfanidou, Christos Liaskos, Daniel S. Smyk, Vassiliki Spyrou, Lazaros I. Sakkas, Eirini I. Rigopoulou & Dimitrios P. Bogdanos. (2013) p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity. Autoimmune Diseases 2013, pages 1-11.
Crossref
Crossref
ID O’Neill & C Scully. (2012) Biologics in oral medicine: ulcerative disorders. Oral Diseases 19:1, pages 37-45.
Crossref
Crossref
Labib R. Zakka, Shawn S. Shetty & A. Razzaque Ahmed. (2012) Rituximab in the Treatment of Pemphigus Vulgaris. Dermatology and Therapy 2:1.
Crossref
Crossref
R.J. Feldman, W.G. Christen & A.R. Ahmed. (2012) Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. British Journal of Dermatology 166:3, pages 511-517.
Crossref
Crossref